Resources

monitor-default-image.png
This week's highlights Equity markets saw a week of sector rotation with cyclical stocks outperforming and technology-related companies lagging. Top performing equity ETFs were in the energy (FUEL), and financial (MVB, QFN, OZF and BNKS) sectors. Low volatility (ZYUS) and value (VVLU) factors outperformed. India funds (IIND and NDIA) were also amongst the top performers. Biotech fund CURE was the poorest performing equity fund for the week, with FANG, ROBO, ESPO and HACK also amongst the poorest performers. Precious metals mostly declined. Platinum (ETPMPT), silver (ETPMAG) and gold (QAU and PMGOLD) were amongst the poorest performers. Palladium (ETPMPD) posted a small gain. Oil fund OOO gained 7.5% for the week and was the overall top performing fund. Total reported flows into domestically domiciled ETFs were $369m, while outflows totalled $252m. Domestic equity fund IOZ and Australian government bond fund AGVT saw the week’s biggest inflows, followed by a range of equity funds including A200, IEM, FAIR and IJR. Cash and variable interest funds AAA, QPON and FLOT saw the bulk of the week’s outflows. VAS was the most traded fund for the week, followed by AGVT, which saw above average volumes. ...
5_biotech_companies_you_should_know_about_-_article_thumbnail_1a4f5f652a.png
Biotechnology came into the spotlight in 2020 as many companies raced to test and register vaccines for COVID-19, however, the potential and growth of this industry extends far beyond the pandemic. Biotechnology is transforming the way we treat and manage a range of health concerns and diseases and can be a highly lucrative space. What is biotechnology? Biotechnology specifically refers to technologies that use biological processes, capturing companies that focus on research, development, manufacturing and/or marketing of products based on biological and genetic information. The different types of biotechnology include biological drugs, vaccines, immunotherapy, gene therapy, orphan drugs and genetic engineering. While Australian companies like CSL Ltd (ASX: CSL) are no slouches when it comes to innovative biotech, the US is typically viewed as the global centre. The dominance of the US market is partly due to the world-renowned US Food and Drug Administration (FDA) approval process and to the size of its customer base. As a result, many companies base themselves in the US for easier access to the process and more efficient ability to distribute and market to US consumers. Global innovators ...